Your first 90 days
Your first 90 days on Elfabrio for Fabry disease
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Elfabrio is a lifelong schedule of IV infusions every 2 weeks rather than a pill. The first weeks are the slowest, because the label starts every patient at a fixed rate and only allows shorter infusions once several have gone well. The first 90 days hold 7 infusions if none is moved. This page lays out that stretch from the FDA label, Chiesi's own Chiesi Total Care materials and one insurer's written rules.
What has to happen before the first bottle ships
Elfabrio has no REMS, so the first infusion waits on a Start Form, an insurance approval and a clinic that can give it safely. These are the 6 things in the way, in order.
The Elfabrio Start Form
Your prescriber's office and you complete one Start Form and fax it to Chiesi Total Care at 1-877-435-2524.
- It records your weight, how Fabry disease was diagnosed, any allergies and your earlier treatment with its last dose.Start Form
Signing up for Chiesi Total Care is optional
The Start Form says enrollment in Chiesi Total Care is not required to receive Elfabrio.
- Signing up lets the program check your insurance, help fill the prescription and review you for copay help.Start Form
The insurance approval
Some plans, such as the FEP policy shown below, require prior approval first.
- Chiesi's Field Reimbursement Managers can help your doctor's office with prior authorization, appeals and denials, according to the program's terms.Enrollment form
Where the first infusions happen
Chiesi's patient brochure says the first 4 to 6 infusions are given in an infusion center or your doctor's office.
- The label requires emergency equipment, including resuscitation equipment, to be on hand during every infusion.Patient brochure
Medicines before the infusion
The label says your prescriber may consider antihistamines, fever reducers or steroids before an infusion.
- If you took these before another enzyme replacement, similar medicines are considered for the first several Elfabrio infusions.FDA label
If you are switching from Fabrazyme or another enzyme replacement
The label says people switching may already carry antibodies that react to Elfabrio.
- These can raise the chance of allergic and infusion reactions and may lower how well Elfabrio works, so your prescriber may track blood tests such as lyso-Gb3.FDA label
The days that matter
Counted from the first infusion, with each infusion 2 weeks apart, the slow starting rate, refills every 28 days and the earliest point the label allows a shorter infusion. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Start Form and the benefits check
The office faxes the Start Form, and Chiesi Total Care checks your coverage and sends the prescription to the right pharmacy.
- No source sets how long this takes, because each insurer works on its own timeline.
Approval, then booking the infusion
Chiesi Total Care says it makes sure the medicine is delivered where you need it and helps find an infusion facility.
- The first infusions are usually booked at a clinic or doctor's office.
First infusion, at the slow starting rate
If you are new to enzyme replacement, this takes at least 4 hours, and about 6 hours over 100kg (220 lb).
- If you are switching, it takes about 3 hours.
- In trials, the 4 anaphylaxis cases began 5 to 40 minutes into the first infusion.
The window for infusion reactions
The label counts any reaction from the start of an infusion until 24 hours after it ends as infusion-related.
- Chiesi says to seek medical care right away if allergy signs come after you leave.
Infusion 2, same slow rate
The label keeps the starting rate for the first 4 to 6 infusions.
- If a dose is missed, it is restarted as soon as possible and then given every 2 weeks, never doubled.
Infusion 3, and the first refill
Chiesi's Start Form asks the pharmacy to dispense a 28-day supply, which covers 2 infusions.
- Vials come in 20mg and 5mg sizes, and the count is rounded up from your weight.
Infusion 4
After 4 to 6 infusions that go well, the label allows a stepwise cut in pre-infusion medicines for people who needed them on an earlier enzyme replacement.
- Your prescriber decides whether to change them.
Infusion 5, and the earliest shorter infusion
Once the first 4 to 6 infusions have gone well, the label lets every third infusion be 30 minutes shorter.
- Shortening happens only in a healthcare facility.
- The second 28-day refill is due around now.
Infusion 6, the last at the starting rate
This is the end of the label's 4 to 6 infusion starting window.
- Home infusion may be considered once you reach an infusion time you tolerate well, after your prescriber evaluates you.
Infusion 7
The third 28-day refill is due.
- The label asks for kidney blood and urine tests during treatment, creatinine and urine protein, but gives no fixed schedule, so your care team sets the timing.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Elfabrio label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated July 8, 2024, read from the FDA's label database today. FDA label
- May 2024
The label added a smaller 5mg vial alongside the 20mg vial and corrected the trial registry number for the head-to-head trial. The dose, infusion rates and warnings did not change.FDA label
- May 2023
The FDA approved Elfabrio for adults with confirmed Fabry disease. The first label already carried the boxed allergy warning, the kidney inflammation warning, the infusion rate tables and home infusion.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- The dose
The label gives 1mg/kg of actual body weight every 2 weeks as an IV infusion.
- The number of vials is rounded up to the next whole vial, so it changes if your weight changes.FDA label
- How the starting rate is set
For the first 4 to 6 infusions, the bag size depends on weight: 150mL under 70kg (154 lb), 250mL from 70 to 100kg, 500mL over 100kg (220 lb).
- People new to enzyme replacement get a slower rate than people switching.FDA label
- If your old treatment took longer than 3 hours
The label says to start Elfabrio at the same rate you had before.
- After the first 4 to 6 infusions, every third infusion may be 30 minutes shorter, down to 1.5 hours.FDA label
- If a reaction happens
For a mild or moderate reaction, staff may pause the infusion for 15 to 30 minutes or slow it by 25% to 50%.
- For a severe reaction such as anaphylaxis, the label says the infusion is stopped right away and treated.FDA label
- After a reaction, the rate builds back slowly
The label raises the rate by 25% every third infusion until it reaches the rate where the reaction happened.
- If an infusion had to be stopped, it may be tried again within 7 to 14 days at a lower rate.FDA label
- Home infusion
The label allows home infusion under a healthcare provider's supervision once you reach a well-tolerated infusion time.
- At home the infusion time stays the same, and it can only be shortened in a healthcare facility.FDA label
- If an infusion is missed
The label says to restart as soon as possible and keep 2 weeks between infusions after that, without doubling a dose.
- For a missed or delayed home infusion, it says to contact a healthcare provider.FDA label
- Pregnancy and breastfeeding
There are no human data on Elfabrio in pregnancy, though the label says an enzyme replacement is not expected to cause harm.
- Chiesi runs a pregnancy safety study at 1-888-661-9260.
- There are no data on breast milk.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs of a severe allergic reaction
Throat tightness, swelling of the face, mouth, lips or tongue, hives, intense itching, a blocked airway, a fast heartbeat or low blood pressure.
- In trials, 14% had allergic reactions and 3% had anaphylaxis.
- Chiesi says to seek immediate medical care if a reaction comes after treatment.FDA label
Infusion reactions
Nausea, chills, itching, rash, chest pain, dizziness, vomiting, headache, flushing, or a fast or slow heartbeat during or within 24 hours of an infusion.
- In trials, 29% had at least one infusion reaction.
- The label asks your care team to explain these signs and says to get medical care right away if they occur.FDA label
Heart strain during reactions
The label says people with advanced Fabry disease and weakened heart function may face more serious complications from an infusion reaction.
- It asks for close monitoring of these patients during infusions.FDA label
Kidney inflammation
One trial patient developed membranoproliferative glomerulonephritis, a kidney inflammation, and kidney function only partly recovered after stopping Elfabrio.
- The label asks for creatinine and urine protein tests, and says to pause treatment if this is suspected.FDA label
Common side effects
In the head-to-head trial against Fabrazyme, the most common were infusion reactions (32%), cold symptoms and headache (21% each), and diarrhea (19%).
- Tiredness and nausea followed (17% each), then back pain, limb pain and sinus infection (15% each).FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedThe FEP policy below asks for age 18 or older, a Fabry disease diagnosis and a prescriber who agrees to watch for allergic reactions during infusions. Chiesi's Field Reimbursement Managers can help the office with denials and appeals.FEP Blue policy
- A copay you cannot payCommercial insurance: the Prescription Copay and Infusion Services Copay programs, each as little as $0. Medicare, Medicaid, TRICARE, VA and other government plans are excluded. Our help paying page lists charity funds that may cover what remains.Chiesi Total Care
- Your plan came from the insurance marketplaceThe program's terms say a commercial plan bought through a marketplace or exchange does not count as government coverage, even with a federal subsidy. That means copay help may still apply.Enrollment form
- You live in or are treated in Massachusetts or Rhode IslandThe program's terms exclude these 2 states from copay help for infusion services and routine testing. Chiesi Total Care also offers no infusion assistance, including home infusion help, there. The Prescription Copay is not part of that exclusion.Enrollment form
- Home infusion support was refusedChiesi Total Care requires a referral to home infusion from your prescribing physician before it supports home infusion. Its brochure also says home infusion depends on insurance and on tolerating Elfabrio first.Chiesi Total Care
- No insuranceChiesi Total Care says uninsured patients may be eligible for financial assistance. Its terms ask for household size, yearly household income and proof of income such as W2 forms, pay stubs or tax returns.Program terms
- Copay help stopped in JanuaryThe program's terms say patients must renew their eligibility by December 31st each year to keep receiving support. Call Chiesi Total Care before the year ends.Enrollment form
Blue Cross Blue Shield Federal Employee Program prior authorization policy, April 1, 2026
- Age 18 or older
- A diagnosis of Fabry disease
- The prescriber agrees to monitor for allergic reactions, including anaphylaxis, during Elfabrio infusions
- Renewal uses the same requirements
Approval length. Two years at a time, for both the first approval and each renewal.
This policy was approved on March 6, 2026 and cites the May 2024 label, which is still the current one. It does not ask for a failed earlier treatment or a specific test result. It is here as an example of what a plan asks for, not as a rule. Other plans may ask for more. FEP Blue policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- Patient Service Managers and Patient Education Liaisons by phone, with pharmacists and nursing support on the wider team
- A Prescription Copay program for commercial insurance, as little as $0 for Elfabrio itself
- An Infusion Services Copay program for commercial insurance, as little as $0 for infusion supplies and administration, including home infusion, except in Massachusetts and Rhode Island
- Financial support is not open to anyone with Medicare, Medicaid, VA or other government coverage, though nonfinancial help still is
- Infusion assistance: help finding an infusion facility, delivery of the medicine to where you need it, and a home infusion eligibility review. It needs a prescriber referral for home infusion and is not offered in Massachusetts or Rhode Island
- Possible financial assistance for people with no insurance. Enrollment uses the Patient Enrollment and Consent Form, faxed to 1-877-435-2524
Details as the drugmaker publishes them. Chiesi Total Care
Five questions for the pharmacist or the support line
- Which pharmacy is sending my Elfabrio, and does it ship to the clinic or to my home?
- Is my dose based on my current weight, and who do I tell if my weight changes?
- Which medicines will I get before each infusion, and when might they be reduced?
- How long will my first infusions take, and when could they get shorter?
- Has my Infusion Services Copay been applied to the clinic's bill as well as the medicine?
- What would I need for home infusion, and does my plan cover it?
Questions people ask in the first weeks
How long does an Elfabrio infusion take?
The first 4 to 6 take at least 4 hours if you are new to enzyme replacement, and about 3 hours if you are switching. After those, the label allows every third infusion to be 30 minutes shorter, down to 1.5 hours. Chiesi says extra time may be needed for pre-infusion medicines.
Can I switch to Elfabrio from Fabrazyme?
Yes, the main trial enrolled adults who had taken Fabrazyme for at least a year. The label warns that people switching may already carry antibodies that raise the chance of reactions or lower drug levels. For people switching from Fabrazyme who carry these antibodies, it suggests tracking response, such as lyso-Gb3 blood levels.
Can I get Elfabrio infusions at home?
The label allows home infusion under a healthcare provider's supervision once you reach an infusion time you tolerate well. Your prescriber makes that decision. Chiesi Total Care needs a referral from your prescriber, and its infusion help is not available in Massachusetts or Rhode Island.
Why does Elfabrio have a boxed warning?
The label's boxed warning covers serious allergic reactions, including anaphylaxis. In trials, 4 people had anaphylaxis 5 to 40 minutes into their first infusion. Emergency equipment must be ready during every infusion, and a severe reaction stops the infusion right away.
Do I need blood or urine tests on Elfabrio?
The label asks for creatinine and urine protein tests because one trial patient developed a kidney inflammation. It sets no fixed schedule. Antibody tests are suggested for people who have reactions, and lyso-Gb3 for some people switching.
Is Elfabrio approved every 4 weeks?
Not in the US. Chiesi and Protalix announced on March 9, 2026 that Europe approved 2mg/kg every 4 weeks for stable adults. Their release says the US-approved dose remains 1mg/kg every 2 weeks.
Can teenagers or children receive Elfabrio?
No, the label covers adults only and says safety and effectiveness have not been established in children. The FDA required Chiesi to study children aged 2 to under 18 after approval.
Free email alert
Hear when the Elfabrio label changes
One email the day the FDA revises the Elfabrio label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Elfabrio only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Fabry disease for new trials, FDA decisions and label changes for every treatment.
Sources
- ELFABRIO (pegunigalsidase alfa-iwxj) injection, for intravenous use, prescribing information, revised May 2024, Chiesi USA, via DailyMed, July 8, 2024.
- ELFABRIO (pegunigalsidase alfa-iwxj) injection, for intravenous use, prescribing information, revised 5/2023, FDA, Drugs@FDA, May 9, 2023.
- BLA 761161 approval letter, Elfabrio (pegunigalsidase alfa-iwxj), FDA, May 9, 2023.
- Elfabrio® (pegunigalsidase alfa-iwxj) support for Patients & Caregivers: Chiesi Total Care℠, Chiesi USA, November 7, 2026.
- Chiesi Total Care Patient Enrollment and Consent Form (PP-RA-00363 V2.0, July 2025), Chiesi USA, August 4, 2025.
- Chiesi Total Care Patient Support Program Terms and Conditions (PP-EF-0130 V3.0), Chiesi USA, October 2, 2023.
- Elfabrio® Start Form (PP-RA-01080 V1.0), Chiesi USA, August 21, 2025.
- Elfabrio patient brochure, For adults with Fabry disease (PP-RA-00032 V2.0), Chiesi USA, December 4, 2025.
- Patient Support & Access Services, Chiesi USA, November 7, 2026.
- ERT Option Overview for Fabry disease, Chiesi USA, November 7, 2026.
- Elfabrio Access Resource Guide (PP-EF-0326 V5.0), Chiesi USA, October 2, 2024.
- Pharmacy Policy 5.30.087, Elfabrio, Blue Cross Blue Shield Federal Employee Program, April 1, 2026.
- Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa), Chiesi and Protalix, via BioSpace (GlobeNewswire), March 9, 2026.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing geneticist. Found an error? Use the report link in the footer and it will be checked against the source.